ANI Pharmaceuticals, Inc. (ANIP) Dividend History

Company News

• ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

  ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million, a 43.4% year-over-year growth. The company's Rare Disease business generated $69.0 million in quarterly net revenues and presented preclinical data on the use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis mouse model.

  GlobeNewswire Inc.
• ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

  ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.

  Benzinga
• ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

  ANI Pharmaceuticals, Inc. announced that it will release its third quarter 2024 financial results on November 8, 2024, and host a conference call to discuss the results.

  GlobeNewswire Inc.
• Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz

  Avadel Pharmaceuticals received FDA approval to expand the label of its narcolepsy drug Lumryz to include treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older. This expands the drug's indication to the pediatric population and is expected to boost sales.

  Benzinga

  Featured Companies: ALNY AVDL
• Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

  Alnylam Pharmaceuticals has submitted a regulatory filing in the EU for its investigational drug vutrisiran to treat ATTR amyloidosis with cardiomyopathy. The filing is supported by positive results from a late-stage study, and if approved, the drug has the potential to become the new standard of care for ATTR-CM treatment.

  Benzinga

  Featured Companies: ALNY FOLD